Accession Number:

AD1101259

Title:

Quantitative Phase Microscopy for Real-Time Clinical Determination of Drug Therapy Response in Primary and Metastatic Breast Cancer

Descriptive Note:

Technical Report,01 Mar 2019,29 Feb 2020

Corporate Author:

University of Utah Salt Lake City United States

Report Date:

2020-03-20

Pagination or Media Count:

13.0

Abstract:

There are no biomarkers that can accurately predict chemotherapy response in advanced cancer patients and less than 10 of patients with a detected targetable mutation are eligible for a clinical trial. There is a need for new diagnostic methods that can accurately stratify high-risk patients to effective, FDA-approved therapies. Our current patient-derived models for assessing tumor drug response require 1-8 months to obtain drug sensitivity profiles making these impractical for patient care. In this project we will develop a functional assay with the new capability to predict cancer cell response to therapy within 2 d of sample collection in terms of both population response and single-cell heterogeneity. In year 1 we have developed the technical platform for this work which will be applied in years 2 and 3. Overall, our project will provide real-time feedback to oncologists on drug sensitivityresistance and resistant subpopulations.

Subject Categories:

  • Medicine and Medical Research
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE